HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ortho's Renova shows "moderate" improvement for fine wrinkles in 24% of patients treated.

This article was originally published in The Rose Sheet

Executive Summary

ORTHO's RENOVA SHOWS "MODERATE" IMPROVEMENT FOR FINE WRINKLES IN 24% OF PATIENTS treated with the anti-wrinkle agent for 24 weeks compared to 8% of patients using a vehicle emollient cream, according to two clinical trials conducted by the Johnson & Johnson subsidiary. Forty percent of Renova patients compared to 30% of vehicle patients showed a minimal improvement in fine wrinkling and 36% of Renova patients compared to 62% of vehicle patients showed no improvement. Renova was approved on Dec. 29 for the mitigation of fine wrinkles, mottled hyperpigmentation and tactile roughness of facial skin. The antiwrinkle agent will be available by prescription in February.
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS002355

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel